Quick Answer
Caribou Biosciences, Inc. reported Cash and Equivalents of $12.36 million for fiscal year 2025.
Caribou Biosciences, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $12.36M | -24.1% |
| 2024 | $16.29M | -68.2% |
| 2023 | $51.16M | -12.3% |
| 2022 | $58.34M | -75.7% |
| 2021 | $240.42M | +1407.1% |
| 2020 | $15.95M | -61.2% |
| 2019 | $41.07M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $11.14M | -65.1% | -55.8% |
| June 30, 2025 | $25.20M | -33.4% | -14.3% |
| March 31, 2025 | $29.42M | -40.5% | +80.5% |
| December 31, 2024 | $16.29M | -68.2% | -49.0% |
| September 30, 2024 | $31.97M | -69.3% | -15.6% |
| June 30, 2024 | $37.87M | -42.8% | -23.3% |
| March 31, 2024 | $49.40M | -6.3% | -3.4% |
| December 31, 2023 | $51.16M | -12.3% | -50.8% |
- Caribou Biosciences, Inc. showed a decrease of -24.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Caribou Biosciences, Inc.’s cash and equivalents has declined by 69.9% (from $41.07 million to $12.36 million).
- The most recent figure is from Caribou Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: